3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Collaborators:
Janssen Pharmaceuticals
OHSU Knight Cancer Institute
Rutgers Cancer Institute of New Jersey
NorthShore University HealthSystem Research Institute
Duke University
Feinberg School of Medicine, Northwestern University
Sidney Kimmel Comprehensive Cancer Center
University of North Carolina
Wayne State University
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01751451
First received: December 14, 2012
Last updated: May 13, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2015
  Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)